Tag: GLORY-2
-
Mazdutide 9 mg Drives Weight Loss as GLORY-2 Trial Meets Endpoints in Obese Chinese Adults
New GLORY-2 Results Highlight Mazdutide’s Potential in Obesity Management Innovent Biologics, in collaboration with partner companies, announced encouraging results from the GLORY-2 study evaluating Mazdutide 9 mg in Chinese adults with obesity. The multi-center trial reports substantial weight loss and favorable safety signals, with reductions reaching as high as 20.1% of baseline body weight for…
-
Mazdutide 9 mg Delivers Notable Weight Loss in Chinese Obesity Patients: GLORY-2 Trial Surpasses Endpoints
Breakthrough in Obesity Treatment: GLORY-2 Report Highlights Mazdutide 9 mg Innovent Biologics and collaborating partners announced compelling results from the GLORY-2 phase 3 trial evaluating Mazdutide 9 mg in adults with obesity in China. The study reports weight loss of up to 20.1% among participants, with the primary endpoint and all key secondary endpoints met.…
-
Mazdutide 9 mg Delivers Up to 20.1% Weight Loss in Chinese Adults: GLORY-2 Study Set to Shape Obesity Treatment
New GLORY-2 Results Highlight Mazdutide 9 mg’s Weight-Loss Potential Innovent Biologics and partners report compelling outcomes from the GLORY-2 trial, evaluating the investigational drug mazdutide 9 mg in Chinese adults with obesity. The study met its primary endpoint and all key secondary endpoints, underscoring mazdutide’s potential to transform obesity management in a population with high…